V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Heron Therapeutics Executive Compensation (FY25)

HRTX · Executive and director compensation, fiscal 2023 to 2025
Data as of September 7, 2026Latest filing (8-K): June 16, 2026
207 figures on this page: 197 cited to the filing that reported them, 10 calculated from figures it prints. See the citations
Craig Collard, Chief Executive Officer, received $3,516,291 in total compensation for fiscal 2025, and Collard's total was 146.8% higher than the $1,424,811 reported for fiscal 2024. Meanwhile, for fiscal 2025, shareholders backed the say-on-pay proposal with 86.5% of votes cast for or against in favor at the meeting held June 11, 2026. Separately, the disclosed peer group includes Akebia Therapeutics, ANI Pharmaceuticals, Coherus BioSciences, Collegium Pharmaceuticals and Esperion Therapeutics, among others. The fiscal 2025 disclosure covers 4 named executive officers.
Chief executive, fiscal 2025
◇
Craig Collard
Latest say-on-pay support
=
June 11, 2026
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Craig Collard: $1,424,811 → $3,516,291 (146.8% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Heron Therapeutics' chief executive and what were they paid?
Craig Collard, Chief Executive Officer, received $3,516,291 in total compensation for fiscal 2025. Collard's total was 146.8% higher than the $1,424,811 reported for fiscal 2024.
What was Heron Therapeutics' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 86.5% of votes cast for or against in favor at the meeting held June 11, 2026.
Which companies are in Heron Therapeutics' peer group?
The disclosed peer group includes Akebia Therapeutics, ANI Pharmaceuticals, Coherus BioSciences, Collegium Pharmaceuticals and Esperion Therapeutics, among others.
What is Heron Therapeutics' chief executive pay ratio?
The company reported a chief executive pay ratio of 13.1:1 for fiscal 2025, against median employee compensation of $268,890.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Craig Collard
Chief Executive Officer
◇—◇◇◇—◇◇
Ira Duarte
EVP, Chief Financial Officer
◇—◇◇◇—◇◇
William Forbes
EVP, Chief Development Officer
◇—◇◇◇——◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
William Forbes
EVP, Chief Development Officer
◇—◇◇◇——◇
Craig Collard
Chief Executive Officer
◇—◇◇◇—◇◇
Ira Duarte
EVP, Chief Financial Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Mark Hensley
Executive Vice President, Chief Operating Officer
◇—◇◇◇—◇◇
Craig Collard
Chief Executive Officer
◇—◇◇◇—◇◇
William Forbes
Executive Vice President, Chief Development Officer
◇—◇◇◇——◇
Ira Duarte
Executive Vice President, Chief Financial Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Craig CollardRSU◇——◇——◇
Craig CollardOPTION◇——◇—◇◇
Ira DuarteRSU◇——◇——◇
Ira DuarteOPTION◇——◇—◇◇
Mark HensleyOPTION◇——◇—◇◇
Mark HensleyOPTION◇——◇—◇◇
Mark HensleyRSU◇——◇——◇
William ForbesRSU◇——◇——◇
William ForbesOPTION◇——◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Ira DuarteOption◇—◇—
RSU◇◇——
Option◇—◇1/31/2035
Option◇—◇1/19/2034
RSU◇◇——
RSU◇◇——
Craig CollardRSU◇◇——
RSU◇◇——
Option◇—◇1/31/2025
Option◇—◇1/19/2034
RSU◇◇——
Option◇—◇4/3/2033
RSU◇◇——
RSU◇◇——
William ForbesOption◇—◇1/19/2034
RSU◇◇——
Option◇—◇6/6/2033
RSU◇◇——
Option◇—◇1/31/2035
RSU◇◇——
Mark HensleyRSU◇◇——
Option◇—◇4/28/2035
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Tom Cusack
◇◇◇———◇
Adam Morgan
Board chair
◇◇◇———◇
Craig Johnson
◇◇◇———◇
Christian Waage
◇◇◇———◇
Michael Kaseta
◇◇◇———◇
Susan Rodriguez
◇◇◇———◇
Sharmila Dissanaike and Craig Collard served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Akebia Therapeutics AKBA
  • ANI Pharmaceuticals ANIP
  • Coherus BioSciences CHRS
  • Collegium Pharmaceuticals COLL
  • Esperion Therapeutics ESPR
  • G1 Therapeutics GTHX
  • Harrow HROW
  • Innoviva INVA
  • Lexicon Pharmaceuticals LXRX
  • Ocular Therapeutics OCUL
  • OptiNose OPTN
  • Phantom Pharmaceuticals PHAT
  • Rigel Pharmaceuticals RIGL
  • Sage Therapeutics SAGE
  • Travere Therapeutics TVTX
  • UroGen Pharma URGN
  • Vanda Pharmaceuticals VNDA
  • Xeris Biopharma Holdings XERS
  • Y-mAbs Therapeutics YMAB

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 11, 2026=◇◇◇
2023June 13, 2024=◇◇◇
2022June 8, 2023=◇◇◇
2021May 24, 2022=◇◇◇
2020June 17, 2021=◇◇◇
2019June 17, 2020=◇◇◇
2018June 18, 2019=◇◇◇
2017June 18, 2018=◇◇◇
2016June 12, 2017=◇◇◇
2015June 21, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Heron Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Heron Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Heron Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Heron Therapeutics' disclosed peer group is defensible, who names Heron Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
207 figures on this page: 197 cited to the filing that reported them, 10 calculated from figures it prints.
197 cited to the filing
10 calculated from the filing

Documents cited

  1. 0001193125-26-272388
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001193125-26-196306
    Executive Compensation Tables · Grants of Plan-Based Awards · INFORMATION CONCERNING THE BOARD OF DIRECTORS
  3. 0000950170-25-060882
    2024 Summary Compensation Table · Executive Compensation Tables
  4. 0000950170-24-074952
    Item 5.07 Submission of Matters to a Vote of Security Holders
  5. 0001140361-24-022881
    Summary Compensation Table
  6. 0000950170-23-027374
    Item 5.07 Submission of Matters to a Vote of Security Holders
  7. 0001564590-22-021277
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001564590-21-033349
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001564590-20-029788
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001193125-19-176468
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001193125-18-201200
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001193125-17-202432
    Item 5.07 Submission of Matters to a Vote of Security Holders
  13. 0001193125-16-628925
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Heron Therapeutics executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/HRTX (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Heron Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Heron Therapeutics discloses

The companies named in HRTX's own disclosed peer group.

Akebia TherapeuticsCoherus BioSciencesEsperion TherapeuticsPhantom PharmaceuticalsTravere TherapeuticsUroGen PharmaVanda PharmaceuticalsXeris Biopharma Holdings

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy